PFIZER INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
PFIZER INC (PFE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $261.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2020-02-27
- PFIZER INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $261.00M, a 58.24% decline from fiscal 2018.
- PFIZER INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2018 was $625.00M, a 88.82% increase from fiscal 2017.
- PFIZER INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2017 was $331.00M, a 14.91% decline from fiscal 2016.
- PFIZER INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2016 was $389.00M, a 41.59% decline from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2019-12-31 | $261.00M 10-K · filed 2020-02-27 |
| 2018-12-31 | $625.00M 10-K · filed 2020-02-27 |
| 2017-12-31 | $331.00M 10-K · filed 2020-02-27 |
| 2016-12-31 | $389.00M 10-K · filed 2019-02-28 |
| 2015-12-31 | $666.00M 10-K · filed 2018-02-22 |
| 2014-12-31 | $458.00M 10-K · filed 2017-02-23 |
| 2013-12-31 | $578.00M 10-K · filed 2016-02-29 |
| 2012-12-31 | $263.00M 10-K · filed 2015-02-27 |
| 2010-12-31 | $5.00M 10-K · filed 2011-02-28 |
| 2009-12-31 | $2.00M 10-K · filed 2011-02-28 |
| 2008-12-31 | $9.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |